11月6日，晶泰控股盘初涨超7%，消息面上，晶泰科技宣布，其全资子公司Ailux与礼来达成多靶点战略合作及平台授权协议，协议总价值最高可达3.45亿美元，其中包括数千万美元的预付款及近期里程碑付款。
礼来将借助Ailux的专有平台加速多个治疗领域的双特异性抗体（双抗）发现与开发，同时利用其AI抗体研发平台加速内部管线的研究。这是继2023年晶泰科技与礼来签订2.5亿美元AI小分子药物合作后双方的再度携手。
据悉，Ailux 是晶泰科技自2021年起重点布局的大分子药物研发平台，并在近两年经历了快速的发展和商业成果转化。Ailux以其干湿结合的研发模式，实现精确的AI抗体药物设计与工程，有效解决药物发现中成本高、周期长的挑战，助力药企探索更丰富的靶向机制和差异化的成药路径。未来，Ailux还将具备将AI设计的多种下一代抗体药物推进至更后期临床阶段的能力，以获得更有影响力的重大商业合作。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
